In the SURMOUNT trials, tirzepatide at 15 mg averaged 22.5 percent body weight loss over 72 weeks, while the 5 mg and 10 mg doses landed roughly in the 15 to 20 percent range
Its a testament to our clinics dedication to staying at the forefront of medical advancements in the field
There is a boxed warning regarding thyroid C-cell tumors based on rodent studies, with a contraindication in patients with personal or family history of MTC or MEN2
Avoid injecting into broken skin, scar tissue, bruised or infected areas, moles, or sites showing signs of lipohypertrophy
Overeating on tirzepatide can lead to significant discomfort nausea, bloating, even vomiting in some cases
renal function should be monitored if significant gastrointestinal losses occur